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Abstract The RET proto-oncogene encodes a receptor tyrosine 
kinase expressed during neural crest development. RET expres-
sion is enhanced in vitro by several differentiating agents, 
including retinoic acid (RA), which up-regulates RET expression 
in neuroblastoma cell lines. In the present work we sequenced and 
analysed a 5 kbp genomic fragment 5' to RET. Three deletion 
fragments of this region were tested for their RA inducibility in 
transient transfection assays and failed to support the hypothesis 
of a direct transcriptional activation. Finally, our functional 
analysis of a candidate RA response element present in the RET 
promoter provides new hints for the understanding of the 
interaction between nuclear receptors and their specific recogni-
tion sites. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The RET proto-oncogene encodes a receptor tyrosine ki-
nase [1,2] predominantly expressed during neural crest devel-
opment and involved in different human neurocristopathies 
[3]. 
Somatic rearrangements of RET are responsible for a var-
iable proportion of papillary thyroid carcinomas (PTC) [4-6], 
while germline RET mutations are associated with the three 
variants of the inherited cancer syndrome known as multiple 
endocrine neoplasia type 2: MEN2A, MEN2B and familial 
medullary thyroid carcinoma (FMTC) [7-9]. Finally, germline 
RET mutations have been repeatedly associated with an au-
tosomal dominant form of the Hirschsprung disease (HSCR) 
[10-13], a congenital disorder of the enteric nervous system 
characterised by a marked genetic heterogeneity [14-17]. 
Recently, the identification of Ret ligand proteins, the glial 
cell line-derived neurotrophic factor (GDNF) [18-20], as well 
as neurturin (NTN) [21,22], and of Ret co-receptors (GDNF 
receptor a and ß [23,24] and NTN receptor [22]) has provided 
new insights into the molecular events leading to Ret signal 
transduction and therefore into the understanding of the 
physiological role of the RET proto-oncogene. 
As suggested by the complex phenotypes which arise from 
mutations in RET, this gene plays a crucial role in neural crest 
development. Its action is specifically required at certain 
stages of embryogenesis and for limited periods of time de-
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pending on the cell type [25,26]. This implies a fine transcrip-
tional regulation, with the involvement of different specific 
transcription factors. 
To date, only a few data have been reported with regard to 
the RET promoter region : a short genomic fragment spanning 
453 bp 5' of the human gene has been analysed, where the 
consensus sequences recognised by AP-2, ETF, GCF and Sp-1 
transcription factors have been identified [27]. The RET tran-
scription start site has been localised and the CAT (chloram-
phenicol acetyltransferase [28]) functional assay, performed 
with a fragment spanning from —167 to +98, has shown 
that this region contains the basal promoter of the gene 
[27]. This initial identification of the RET regulatory region, 
far from being exhaustive, can be regarded as a starting point 
for further studies aimed at the identification of the factors 
which regulate RET expression. 
Recent evidence has been collected on the in vitro activa-
tion of RET expression by a variety of differentiating agents. 
Increased RET mRNA levels are observed in TT cells derived 
from medullary thyroid carcinoma following dibutyryl-cAMP 
treatment [29], and in several neuroblastoma (NB) cell lines 
upon treatment with retinoic acid (RA) [30], as well as with 
12-0-tetradecanoyl phorbol-13-acetate (TPA), a-, γ-interferon 
and glial cell conditioned medium (GCM), all of them induc-
ing a neuronal phenotype [31]. NB is an embryonic tumour 
that arises in tissues of the peripheral nervous system [32]; NB 
cell lines, which retain many phenotypic features of the tissue 
from which they originate, provide a natural model system for 
the study of RET expression. In NB cells, RA has been shown 
by Bunone et al. [31] to exert its action by enhancing the level 
of RET transcription rather than by increasing the stability of 
RET mRNA ; moreover, this effect does not require de novo 
protein synthesis [31]. These findings suggest that the regula-
tion of RET expression might be mediated by a direct effect of 
RA on the gene regulatory region. 
RA, a natural derivative of vitamin A, has profound effects 
in a variety of biological processes and plays a crucial role 
during embryogenesis [33-37], especially in neural crest devel-
opment. RA acts at the transcriptional level through nuclear 
receptors which are members of the steroid/thyroid hormone 
receptor superfamily. Retinoid receptors include RAR (all-
trans retinoic acid receptor) a, ß and γ isoforms, and RXR 
(9-cis retinoic acid receptor) α, β and γ isoforms [38^43]. 
RARs and RXRs form functionally active heterodimers [44] 
which recognise retinoic acid response elements (RAREs) 
within the regulatory regions of their target genes. Typical 
RAREs are composed of direct repeats of a core motif 
5'-PuG(G/T)TCA-3' or closely related sequences [40,45^17] 
spaced 1-5 bp apart (DR1-DR5). Nonetheless, several natural 
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response elements contain half-site arrangements which are 
more complex and/or more widely spaced than prototypic 
D R 1 - D R 5 elements [48-50]. Moreover, a systematic study 
of widely spaced D R elements, separated by up to 150 bp, 
has been reported, showing that these sequences can act as 
functional R A R E s [51]. 
In the present work, we completed our previous character-
isation of the genomic region encompassing the entire human 
RET gene [52] by analysing the regulatory 5' region. Given 
the crucial role of R A during neural crest development, we 
investigated the mechanism of the response of RET to R A 
treatment. To this purpose, we coupled different fragments 
of the RET promoter to the prokaryotic CAT gene and 
studied their inducibility in transient transfection assays in 
HeLa and neuroblastoma CHP134 cells. 
2. Materials and methods 
2.1. Plasmici construction, sequence determination and analysis 
A 6.3 kbp BamHl-Xhol fragment isolated from cosmid cretl [27,52] 
was cloned in pBluescript SK~ (Stratagene) and sub-cloned to allow 
for sequencing (PrBX clone, see Fig. 1). The sequence was determined 
by the dideoxynucleotide chain termination method either manually, 
using a USB sequenase 2.0 DNA sequencing kit (Amersham), or 
automatically, using an ABI-PRISM cycle sequencing kit for the 
ABI373 DNA sequencer (Applied Biosystems, Perkin-Elmer). The 
complete sequence obtained was submitted to GenBank under acces-
sion number GenBank AF032124. A collection of transcription factor 
recognition sites described by Faisst and Meyer [53] and by Leonard 
[54], and a representative group of RARE motifs [50,55-62] were used 
to search the available sequence for relevant sites (Fig. 2). 
For transient transfection assays, three CAT gene reporter con-
structs were prepared in pCATBasic (Promega): МаеЗРСАТ, dAccI-
CAT and dStuICAT (see Fig. 1). МаеЗРСАТ was prepared as fol-
lows: the 6.3 kbp Xhol-ВатШ fragment was partially digested with 
Maell restriction endonuclease ; a 5109 bp band (from —5056 to +53) 
was isolated, cloned into the Clal sites of the pBluescript vector (Stra-
tagene) and subsequently transferred into the Xbal-Hindlll sites of 
the pCATBasic vector (Promega). Two deletion clones were derived 
from МаеЗРСАТ by taking advantage of the Acci and Stul restriction 
sites, giving respectively the dAccICAT (from —3528 to +53) and 
dStuICAT (from -1296 to +53) constructs. 
The positive control clone for RA responsiveness (a DR5 element 
cloned in pBLCAT2 vector) and the negative control clone 
(pBLCAT2 vector alone) were a gift of Prof. P. Chambon (Institut 
de Génétique et de Biologie Moléculaire et Cellulaire, Strasbourg, 
France). The RETDR16 and WildDRlö reporter gene constructs 
were produced by inserting synthetic oligonucleotides carrying the 
Hindlll-Saä sites into the corresponding sites of pBLCAT2; the in-
sert sequence of RETDR16 was AAGCTTGGATCCCTTGGAG-
GTCATTCATTGCTTCTGAGCAGGTGAAGATTGTCGAC, while 
the insert sequence of WildDR16 was AAGCTTGGATCCCTTG-
GAGGTCATTCATTGCTTCTGAGCAGGTCAAGATTGTCGAC, 
displaying a single mismatch (C/G) from the RETDR16 insert se-
quence in the second RARE motif. 
2.2. Cell culture and RA treatment 
Neuroblastoma CHP134 cells were a gift of Prof. Della Valle (Isti-
tuto di Genetica Biochimica ed Evoluzionistica, Università di Pavia, 
Italy). CHP134 and HeLa cells were grown in Dulbecco's modified 
Eagle medium (Hyclone) supplemented with 10% foetal calf serum 
(FCS) (Gibco BRL), 2 mM L-glutamine, 100 U/ml penicillin and 
100 μg/ml streptomycin at 37°C in a humidified atmosphere with 
5% CO2. RA treatment was performed as follows: ali-trans RA (Sig-
ma-Aldrich) was dissolved in 100% ethanol and added to the cell 
medium containing 10% charcoal-treated FCS, to a final concentra-
tion of 1 μΜ RA and 0.1% ethanol. In control samples, ethanol alone 
was added to medium containing 10% charcoal-treated FCS. 
2.3. Transient transfection and CAT assay 
The day before transfection, cells were seeded in 100 mm dishes at 
80% confluence. Transfection in HeLa cells was performed with 20 μg 
DNA using a modified calcium-phosphate co-precipitation method 
[63]; transfection in neuroblastoma CHP134 cells was performed us-
ing a modified protocol of the recently described [64,65] PEI (poly-
ethyleneimine) technique. 10 μg DNA was diluted into 300 μΐ medium 
devoid of serum and antibiotics and mixed to 30 μΐ of 10 mM PEI 
(25 kDa, Sigma-Aldrich) (300 mmol PEI/mg DNA). The DNA/PEI 
mixture was vortexed, incubated for 10 min at RT and diluted into 
3 ml complete medium. Cells were depleted of medium prior to addi-
tion of the transfection mixture. After 2 h the transfection mixture 
was removed, cells washed with phosphate-buffered saline (PBS) and 
fresh medium added. The DNA transfection mixture consisted of 7 μg 
of promoter construct and 3 μ% of pCMV-ßgal (Clontech) containing 
the ß-galactosidase coding sequence under the control of the CMV 
(cytomegalovirus) promoter; in HeLa cells 250 ng of either RARa or 
RXRa expression vectors (kindly provided by Prof. P. Chambon) 
were added to the transfection mixture. Total DNA in the transfection 
mixture was kept constant by adding pBluescript plasmid DNA. 
Two days after transfection, cells were collected by scraping in 
300 μΐ of 250 mM Tris-HCl (pH 7.8) and lysed by freezing and 
thawing. Transfection efficiency was determined by spectrophotomet-
ric titration of the ß-gal activity in cell lysates. Amounts of cell ex-
tracts with equivalent ß-gal activity were used in CAT reactions. CAT 
activity was measured using acetyl-CoA and [14C]chloramphenicol as 
described by Gorman [28]; CAT reactions were run on thin layer 
chromatography silica gels and scintillation counting of the spots 
was performed. 
Each transfection presented in this report was performed with du-
plicate samples and was repeated at least three times. 
2.4. Northern blot analysis 
Cytoplasmic RNA was extracted as described by Buckler et al. [66]. 
20 μg RNA was fractionated by 1% agarose/2.2 M formaldehyde gel 
electrophoresis, blotted onto nylon membranes (Hybond), and hybrid-
ised to 32P-labelled cDNA probes according to standard procedures 
[63]. A full-length RET cDNA fragment (4.5 kbp) was used as a 
probe. To normalise for housekeeping gene expression, we used a 
983 bp human glyceraldehyde-3-phosphate dehydrogenase (G3PDH) 
cDNA probe obtained by RT-PCR using commercially available 
primers (Clontech). 
3. Results 
3.1. Physical characterisation and sequence analysis of the 
5' genomic region of the RET gene 
An Xhol-BamHl 6.3 kbp genomic fragment was isolated 
from a cosmid clone (cretl) [27,52] containing the 5' port ion 
of the RET gene and cloned in pBluescript (indicated in Fig. 1 
as PrBX). PrBX contains 5075 bp upstream of the transcrip-
tion start site, the first exon and part of the first intron of the 
Table 1 
Search for RARE single motifs within the RET 5' flanking region 
RARE half-site 
1) AGTTCA 
2) GGTTCA 
3) AGGTCA 
4) AGGGCA 
5) GGGTCA 
6) AGGTGA 
7) AGGTTA 
8) CGGCCA 
No. of sites on 
the + strand 
1 
5 
2 
1 
2 
No. of sites on the 
— strand 
1 
2 
1 
5 
6 
1 
Single half-motifs were derived from natural RAREs present in the 
promoter sequence of mammalian genes encoding: the mouse RAR-
a2 isoform (1 [55]), the human and mouse RAR-ß2 isoform (1 and 2 
[56,57]), the mouse complement factor H (3 and 4 [58]), the human 
alcohol dehydrogenase (1 and 5 [59]), the rat cardiac myosin heavy 
chain a subunit (3 and 6 [60]), the mouse laminin Bl (3, 6 and 7 [50]) 
and the rat phosphoenolpyruvate carboxykinase (8 [61,62]). The table 
shows the number of sites found in the RET promoter on the sense 
(+) and antisense (—) strands. 
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Fig. 1. Physical map of the RET gene 5' flanking region. The 6.3 kbp clone is indicated as PrBx, and the transcription start site and the first 
exon of the gene are located within it. A restriction map of the clone is shown, where only relevant sites recognised by Smal, Stul and Maell 
(indicated by asterisks) are shown. A dotted box underlines the sequenced region. CAT gene reporter constructs are represented by thick 
striped boxes. 
gene. PrBx was then sub-cloned and almost fully sequenced 
(GenBank accession number GenBank AF032124). 
A computer analysis of the available sequence, summarised 
in Fig. 2, revealed the presence of putative recognition sites 
for several transcription factors [53]. Among them there are 
widely expressed transcriptional regulators (AP-2, E2A, GCF, 
PEA3 and Spi), inducible nuclear factors (ISGF1, 2, 3, STAT 
factors and MEP1), as well as developmentally regulated, tis-
sue-specific transcription factors (krox-20, krox-24, TTF1 and 
WT1). Our preliminary sequence analysis also included the 
search for candidate RAREs, which could provide a useful 
tool for any subsequent functional analysis. As shown in 
Table 1, a selected group of RARE half-motifs from mamma-
lian gene promoters [50,55-62] was used to search for single 
Fig. 2. Sequence analysis. Transcription factor recognition sites and RARE motifs are indicated by symbols and positioned along the RET 
5' flanking region (from —5075 to translation start site). Where black and white symbols are present along the same line, the former represent 
sequences displaying 100% homology to the consensus sequence, while the latter display over 80% homology. Where not indicated, the homol-
ogy of sites to the consensus sequence is 100%. Candidate RARE direct repeats are outlined by arrows and indicated as DR16, DR45, DR60 
and DR78, the number reflecting the length of the spacer sequence. 
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Fig. 3. Northern analysis of RET RA responsiveness in CHP134 
cells. Cytoplasmic RNA was extracted from untreated cells (UN) 
and cells treated with 1 μΜ RA (RA) for 1 day and analysed by 
Northern blot. A: Hybridisation with a RET cDNA full-length 
probe. The four major RET transcripts are indicated by arrows ; the 
4.5 and 3.9 kbp mRNAs are evident on the left-hand side, while to 
detect the longer 6.0 an 7.0 kbp mRNAs a prolonged film exposure 
was necessary (right-hand side). B: Hybridisation with a human 
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) 983 bp RT-
PCR product. 
RARE sites: a total of 27 such sequences were identified. 
Taking into account that even widely spaced directly repeated 
RARE half-motifs have been shown to behave as functional 
RAREs, with the maximum transactivating power displayed 
by DR15 [51], only four direct repeats, in which the spacer 
sequence was shorter than 100 bp, were considered as candi-
date RAREs and are outlined in Fig. 2. 
3.2. Northern analysis of RA responsiveness in 
NB CHP134 cells 
The neuroblastoma CHP134 cell line was chosen as a model 
system for our study since it showed a relevant RA-induced 
activation of RET expression among several NB cell lines [31]. 
In order to confirm this activation, we performed Northern 
blot analysis on cytoplasmic RNA extracted from CHP134 
cells untreated and treated with RA for 1 day. As shown in 
Fig. 3, in RA-treated cells all four RET major transcripts (7.0, 
6.0, 4.5 and 3.9 kbp) are expressed, although at different in-
tensities, while only the 4.5 kbp transcript is detectable in 
untreated cells. This finding, together with the evidence al-
ready presented by others [30,31], prompted us to study the 
RA responsiveness of the RET gene at the transcriptional 
level. 
3.3. Transient transfection assays in HeLa and 
NB CHP134 cells 
In order to elucidate the mechanism of RET responsiveness 
to RA, we produced three CAT reporter gene constructs: 
МаеЗРСАТ, dAccICAT and dStuICAT, containing respec-
tively the -5056/+53, -3528/+53 and -1296/+53 regions of 
the RET promoter 5' to the CAT gene (Fig. 1). These con-
structs were tested for their retinoic acid sensitivity in transi-
ent transfection assays either in neuroblastoma CHP134 cells, 
which express endogenous retinoid receptors, or in HeLa cells, 
an ideal neutral recipient for the study of RA-responsive gene 
promoters. By cotransfecting HeLa cells with retinoid recep-
tor expression vectors (such as RAR-α and RXR-oc) it is 
possible to create a responsive cellular system. 
A DR5 natural RARE cloned upstream of the herpes sim-
plex virus thymidine kinase promoter (TK) in the pBLCAT2 
vector was used as a positive control of RA responsiveness, 
while the TK promoter alone present in pBLCAT2 was taken 
as a negative control. The three RET promoter constructs 
were tested for their inducibility following 24 h RA treatment. 
As shown in Fig. 4, despite the definite activation displayed by 
the positive control of responsiveness (over 45-fold in the 
HeLa system; 7-fold in neuroblastoma cells), the МаеЗРСАТ 
construct CAT activity was not enhanced upon RA treatment 
in either cell line. An identical behaviour was displayed by the 
dAccICAT and dStuICAT constructs analysed (data not 
shown). 
Fig. 4. Transient transfection assays in HeLa (A) and neuroblastoma CHP134 (В) cells. Equal amounts of protein extracts from transfected 
cells, untreated (UN) and treated with 1 μΜ RA for 1 day (RA) were used to assay the CAT activity. The positive control of RA responsive-
ness is indicated as +, while the negative control is indicated as —. The RET promoter construct analysed is indicated as МаеЗРСАТ. 
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3.4. Functional analysis of the RETDR16 candidate 
RARE sequence 
The data presented above did not rule out the existence of 
functional RAREs in the gene regulatory region, the activity 
of which might be overridden by negative transcription regu-
lators acting on the long promoter regions analysed. To test 
the hypothesis that the negative data obtained so far were due 
to the use of long promoter constructs, we decided to perform 
functional analysis on isolated candidate RAREs. Four such 
sequences were available for our study (see Fig. 2): among 
them, a AGGTCA(N)i6AGGTGA direct repeat present at 
—2972 on the minus strand of the RET promoter was the 
object of our attention. This sequence is in fact closely related 
to the DR15 motif analysed in the previously mentioned re-
port [51], the directly repeated consensus sequence being the 
same in the two cases, apart from a single G/C mismatch. The 
RET candidate RARE (RETDR16) and a perfect direct 
repetition of the consensus motif AGGTCA (WildDR16) 
were cloned upstream of the heterologous TK promoter in 
pBLCAT2. In both constructs spacer and flanking sequences 
surrounding the RARE half-site were the ones present in the 
RET promoter region. RETDR16 and WildDR16 were tested 
for their RA inducibility as described above. Neither 
RETDR16 nor WildDR16 displayed any significant RA-medi-
ated activation (data not shown). 
4. Discussion 
In the present work we completed our previous character-
isation of the physical map of the RET proto-oncogene ge-
nomic region by analysing 5075 bp upstream of the transcrip-
tion start site. 
A preliminary analysis of this sequence allowed the identi-
fication of putative recognition sites for several transcription 
factors. In particular, some of them display an expression 
pattern which is closely related to that of the RET proto-
oncogene and are likely to play a role in the control of 
RET expression during development: AP-2 and krox-20 are 
in fact most abundant in the neural crest lineage; krox-24 is 
involved in nervous system development; while TTF1 is 
largely responsible for thyroid-specific gene expression and 
WT1 is thought to regulate transcription during kidney devel-
opment [53]. In each of these tissues RET expression has been 
documented during development [25,26]. Our CAT reporter 
gene constructs provide an experimental system to further 
investigate the role of these factors in the control of RET 
transcription under different experimental conditions. 
In order to study the regulation of RET expression pro-
moted by RA we used two simple approaches: Northern 
blot analysis and transient transfection assays. Northern 
blot analysis has revealed a positive role of RA in the control 
of RET expression in neuroblastoma cell lines, which repre-
sent a valuable system for the study of neural crest cells gene 
expression. This is consistent with the evidence already pre-
sented by others [30,31]. The up-regulation of RET expression 
is an early event promoted by RA treatment, which induces a 
series of complex phenotypic changes that result in cellular 
differentiation [31]. In order to further investigate the role 
of RET in RA-mediated cellular differentiation it could be 
of interest to analyse the expression of the newly identified 
-RüTligand and coreceptor molecules [18-23] upon RA treat-
ment. The observation of a concerted RA-mediated up-regu-
lation of all or a part of these genes would confirm the phys-
iological role of retinoids in activating the RET signalling 
machinery during cellular differentiation. A preliminary indi-
cation in this sense comes from the observation, made in our 
laboratory, of the activation of GDNFR-a gene expression 
after RA treatment (unpublished results). 
Our CAT reporter gene approach provides a preliminary 
evidence for the lack of a direct transcriptional effect mediated 
by RA receptors on the RET promoter. It can be suggested 
that RA might regulate RET expression through a more com-
plex mechanism than direct RAR/RXR-mediated transactiva-
tion. Among the transcription factors which are likely to reg-
ulate RET transcription, AP-2 and krox-20 are induced by 
RA [53] and could be responsible for RET indirect response 
to RA treatment. 
Nonetheless, the presence of a DR16 element and other 
RARE-like sequences within the gene regulatory region sug-
gests another possible explanation for our data. The con-
structs analysed contain long genomic regions where the rec-
ognition sites for negative regulators of RET transcription 
(such as GCF, see Fig. 2) could mask the RA-mediated acti-
vation. In fact, an increased level of RET expression has been 
observed in NB cells by inhibiting protein synthesis with cy-
cloheximide [31], suggesting that negative regulators of tran-
scription could be normally associated with the RET regula-
tory region. 
Our functional analysis of the RET DR16 element seems to 
rule out the possibility that the negative data presented here 
were due to the use of long promoter constructs. It could still 
be argued that RAREs might be present in additional regu-
latory regions which are not included in our constructs and 
are still to be identified. 
Our comparative analysis of the RETDR16 and WildDR16 
indicates that neither sequence behaves as a functional 
RARE; this is in apparent disagreement with data reported 
by others, showing that the spacer length between the half-
motifs could be as high as 150 bp [51]. Since spacer between 
the half-sites and flanking sequences are derived from the 
RET promoter region, our results would suggest that such 
sequences are important to define a functional RARE and 
may therefore not allow for nuclear receptor-mediated trans-
activation. Evidence is being collected on this point, indicating 
a growing complexity in the molecular aspects involved in the 
recognition between nuclear receptors and their cognate DNA 
elements [67-70]. In particular it has been suggested that the 
promoter context in which a specific element is placed can be 
the determining factor for nuclear receptor selectivity, being 
capable of overriding the affinity of transcription factors for 
their cognate binding sites. To further investigate this topic we 
could envisage developing a functional analysis of DR16 car-
rying selected and diverse spacer sequences. 
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